Anticoagulants, antiplatelets and fibrinolytics
Where each antithrombotic acts on platelets, the coagulation cascade and fibrin, how the classes differ in kinetics and monitoring, and how each is reversed.
By the end of this page you should be able to
- Map heparins, warfarin, the direct oral anticoagulants, antiplatelet drugs and fibrinolytics to their sites of action.
- Compare unfractionated heparin with low molecular weight heparin in mechanism, kinetics, monitoring and reversal.
- Explain the mechanism, slow onset and interactions of warfarin.
- Describe the direct thrombin and factor Xa inhibitors and their specific reversal agents.
- Explain how fibrinolytics work and why bleeding is their main hazard.
Three targets
Thrombus has three parts that drugs attack separately. Platelets dominate arterial thrombus (white clot, high shear), so arterial disease is treated with antiplatelet drugs. Thrombin and fibrin generation dominate venous thrombus (red clot, stasis), so venous disease is treated with anticoagulants. Formed fibrin is dissolved by fibrinolytics, which convert plasminogen to plasmin. Reversal follows the same logic: a platelet problem needs platelets, a factor problem needs the missing factors or a specific antidote, and a fibrinolytic problem needs an antifibrinolytic.
Heparins
- Mechanism: heparin binds antithrombin and speeds its inactivation of thrombin (IIa) and factor Xa about a thousandfold. Inhibiting thrombin needs a chain long enough to bridge antithrombin and thrombin (at least 18 saccharides); inhibiting Xa needs only the pentasaccharide sequence.
- Unfractionated heparin: large, variable chains; anti-IIa and anti-Xa roughly equal. Binds plasma proteins, endothelium and macrophages, so its effect is unpredictable and dose-dependent clearance makes the half-life lengthen as the dose rises. Given IV or subcutaneously, monitored with the aPTT or anti-Xa level, short-acting and fully reversible, which suits patients likely to need a procedure or with severe renal impairment.
- Low molecular weight heparin (enoxaparin, dalteparin): shorter chains, mostly anti-Xa. Less protein binding, so a predictable response by weight, long subcutaneous half-life and renal clearance (accumulates in renal impairment). Usually not monitored; anti-Xa levels in renal impairment, pregnancy and extremes of weight.
- Fondaparinux: the synthetic pentasaccharide alone; pure indirect anti-Xa, renally cleared, no heparin-induced thrombocytopenia cross-reactivity in practice.
- Heparin-induced thrombocytopenia: antibodies against heparin and platelet factor 4 complexes activate platelets. The platelet count falls (usually 5 to 10 days in) and the patient is prothrombotic, not bleeding. Stop all heparin and use a non-heparin anticoagulant.
- Reversal: protamine, a basic protein that binds acidic heparin. Fully reverses unfractionated heparin, only partly reverses low molecular weight heparin, does not reverse fondaparinux. Can cause hypotension and anaphylactoid reactions, and itself has anticoagulant activity in excess.
Warfarin
- Mechanism: inhibits vitamin K epoxide reductase (VKORC1), so vitamin K cannot be recycled to the reduced form needed to carboxylate factors II, VII, IX and X and proteins C and S.
- Slow onset: existing factors must decay. Factor VII (short half-life) falls first, which raises the INR within a day or two, but full anticoagulation waits for prothrombin (half-life about 3 days). Protein C also falls early, which explains the early prothrombotic window and skin necrosis, and why heparin overlaps warfarin when treating thrombosis.
- Kinetics: well absorbed, highly protein bound to albumin, small volume of distribution, hepatic metabolism mainly by CYP2C9 (the more potent S enantiomer). Genetic variants in CYP2C9 and VKORC1 change sensitivity.
- Interactions: enzyme inhibitors (amiodarone, metronidazole, fluconazole, macrolides) raise the INR; enzyme inducers (rifampicin, carbamazepine) lower it; antibiotics that reduce gut flora, liver disease and poor intake raise it; vitamin K rich food lowers it. Antiplatelets and NSAIDs add bleeding risk without changing the INR.
- Monitoring: the INR, a standardised prothrombin time.
- Reversal: vitamin K (acts over hours because new factors must be made) and, for major bleeding, prothrombin complex concentrate (Prothrombinex-VF in Australia: factors II, IX and X) for immediate replacement, with fresh frozen plasma as an adjunct where factor VII is needed. Doses follow local protocol and the Australian Medicines Handbook.
Direct oral anticoagulants
- Direct thrombin inhibitor: dabigatran, a prodrug that binds thrombin directly (free and clot-bound) without antithrombin. Low oral bioavailability, about 80% renally excreted, so it accumulates quickly in renal impairment; it is dialysable. Prolongs the thrombin time and aPTT.
- Factor Xa inhibitors: rivaroxaban and apixaban bind Xa directly. Mixed renal and hepatic clearance (apixaban least renal), CYP3A4 and P-glycoprotein substrates, so strong inhibitors and inducers of both matter. Highly protein bound, so not dialysable.
- Advantages and limits: fixed dosing, rapid onset and offset, few food interactions, no routine monitoring. Not for mechanical heart valves or antiphospholipid syndrome with arterial events; caution in severe renal impairment.
- Testing: routine tests are unreliable. A normal INR or aPTT does not exclude a meaningful effect; drug-calibrated anti-Xa assays (for Xa inhibitors) and the dilute thrombin time (for dabigatran) estimate levels.
- Reversal: idarucizumab, a humanised antibody fragment that binds dabigatran; andexanet alfa, a decoy inactive factor Xa, for the Xa inhibitors where available; otherwise prothrombin complex concentrate, with timing of the last dose and renal function guiding the decision.
Antiplatelet drugs
- Aspirin: irreversibly acetylates COX-1, stopping platelet thromboxane A2 for the life of the platelet (about 7 to 10 days) because platelets have no nucleus to make new enzyme. Endothelium recovers its prostacyclin, so low doses favour an antithrombotic balance.
- P2Y12 inhibitors block ADP-mediated activation. Clopidogrel is a prodrug activated by CYP2C19 (poor metabolisers get less effect) and binds irreversibly. Prasugrel is a prodrug with more reliable activation and also irreversible. Ticagrelor is active itself and reversible, with dyspnoea and bradyarrhythmia as distinctive side effects.
- Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) block the final common pathway of aggregation, fibrinogen bridging between platelets; IV only, used in selected PCI.
- Dipyridamole inhibits phosphodiesterase and adenosine reuptake; it enhances the effect of adenosine.
- Reversal: none specific. Effects of irreversible drugs last until new platelets are made; platelet transfusion helps in life-threatening bleeding but is less effective while active ticagrelor is still circulating.
Fibrinolytics
- Mechanism: plasminogen activators convert plasminogen to plasmin, which degrades fibrin into fibrin degradation products, including D-dimer.
- Fibrin specificity: alteplase and tenecteplase activate plasminogen bound to fibrin more than circulating plasminogen. Tenecteplase has a longer half-life and more fibrin specificity, so it is given as a single bolus. Streptokinase is not fibrin specific and is antigenic.
- Uses: STEMI when timely PCI is unavailable, selected acute ischaemic stroke, massive pulmonary embolism with shock.
- Hazards: bleeding, above all intracranial haemorrhage, which is why the contraindication checklist matters more than any other step. Reperfusion arrhythmias and, with streptokinase, hypotension and allergy.
- Reversal: stop the infusion; tranexamic acid, a lysine analogue that blocks plasminogen binding to fibrin, and cryoprecipitate to replace fibrinogen, guided by local protocol.
Making the answer flow
- Start with the site of action on a drawn cascade and platelet, then mechanism, kinetics, monitoring, adverse effects, interactions and reversal. The same frame works for every drug in the topic.
- Separate "what tells me it is working" from "what reverses it": the INR for warfarin, aPTT or anti-Xa for heparin, and drug-specific assays for direct agents.
- Link the kinetics to the clinical decision: renal clearance explains accumulation, long platelet life explains why stopping aspirin takes a week to matter.
Where marks are lost
- Saying warfarin acts on vitamin K itself rather than on the enzyme that recycles it.
- Forgetting proteins C and S, and so missing the early prothrombotic phase.
- Treating heparin-induced thrombocytopenia as a bleeding problem.
- Claiming protamine fully reverses low molecular weight heparin or fondaparinux.
- Using a normal INR to clear a patient on a direct oral anticoagulant.
- Calling clopidogrel active, or ticagrelor irreversible.
Where this meets intensive care
- Unfractionated heparin binds antithrombin and inhibits thrombin and factor Xa; it is fully reversible with protamine, which is why it is preferred where rapid reversal or renal failure matters.
- Heparin resistance can reflect low antithrombin or high heparin-binding proteins; bivalirudin, a direct thrombin inhibitor, does not need antithrombin.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Compare unfractionated heparin with enoxaparin.
Show answer
- Both act through antithrombin; unfractionated heparin inhibits IIa and Xa equally, enoxaparin mainly Xa because short chains cannot bridge antithrombin to thrombin.
- Unfractionated: variable protein binding, unpredictable response, aPTT or anti-Xa monitoring, short half-life, fully reversed by protamine.
- Enoxaparin: predictable by weight, subcutaneous, longer half-life, renally cleared, usually unmonitored, only partly reversed by protamine.
- Unfractionated heparin preferred when a procedure is likely or renal function is poor.
- Lower rate of heparin-induced thrombocytopenia with low molecular weight heparin.
- 2.
Why does a patient started on warfarin have a raised INR before they are fully anticoagulated?
Show answer
- Warfarin stops new carboxylated factors being made; existing factors decay by their half-lives.
- Factor VII has the shortest half-life, so it falls first and the prothrombin time and INR rise early.
- Prothrombin (factor II) has the longest half-life and determines the full antithrombotic effect, which takes several days.
- Proteins C and S also fall early, creating a transient prothrombotic state; hence heparin overlap for thrombosis.
- 3.
A patient on warfarin is started on a new drug and the INR rises sharply. Explain possible mechanisms.
Show answer
- Inhibition of CYP2C9 metabolism of S-warfarin (amiodarone, metronidazole, fluconazole).
- Displacement from albumin is a minor, transient effect because free drug is also cleared faster.
- Reduced vitamin K from altered gut flora or poor intake.
- Reduced synthesis of factors in liver dysfunction or hyperthyroidism (increased factor catabolism).
- Distinguish from pharmacodynamic interactions that add bleeding risk without changing the INR (aspirin, NSAIDs).
- 4.
Describe heparin-induced thrombocytopenia.
Show answer
- Immune mediated: IgG against heparin and platelet factor 4 complexes binds platelet Fc receptors and activates them.
- Platelet count falls by more than half, usually 5 to 10 days after starting, earlier with recent exposure.
- Thrombosis, arterial or venous, is the danger; bleeding is uncommon.
- Management: stop all heparin including flushes, start a non-heparin anticoagulant, avoid platelet transfusion and warfarin until the count recovers.
- 5.
How do the direct oral anticoagulants differ from warfarin?
Show answer
- Act directly on thrombin (dabigatran) or Xa (rivaroxaban, apixaban) rather than on factor synthesis.
- Rapid onset and offset; fixed dosing without routine monitoring.
- Fewer food interactions but CYP3A4 and P-glycoprotein interactions; dependence on renal function, especially dabigatran.
- Not suitable for mechanical valves or high-risk antiphospholipid syndrome.
- Specific reversal agents: idarucizumab for dabigatran, andexanet alfa for Xa inhibitors; standard tests unreliable for measuring effect.
- 6.
Explain why aspirin has a prolonged antiplatelet effect despite a short plasma half-life.
Show answer
- Aspirin irreversibly acetylates a serine in COX-1.
- Platelets are anucleate and cannot make new COX-1, so thromboxane A2 production is lost for the platelet lifespan.
- Recovery depends on new platelets, about 10% a day, so most function returns over about a week.
- Endothelial cells regenerate COX and prostacyclin, preserving an antithrombotic balance at low doses.
- 7.
Compare clopidogrel and ticagrelor.
Show answer
- Both block the platelet P2Y12 ADP receptor.
- Clopidogrel: prodrug, activated by CYP2C19 (variable response, poor metabolisers), irreversible binding, slower onset.
- Ticagrelor: active drug, reversible binding, faster and more consistent effect, twice daily.
- Ticagrelor side effects: dyspnoea, bradyarrhythmia, raised uric acid.
- Implication for surgery and bleeding: offset follows platelet turnover for clopidogrel but drug clearance for ticagrelor.
- 8.
How do fibrinolytics work and what limits their use?
Show answer
- Plasminogen activators generate plasmin, which degrades fibrin.
- Fibrin-specific agents (alteplase, tenecteplase) favour clot-bound plasminogen; streptokinase is non-specific and antigenic.
- Benefit is time dependent: the earlier the reperfusion, the more tissue saved.
- Main risk is bleeding, especially intracranial; absolute and relative contraindications screen for it.
- Reversal: stop the drug, antifibrinolytic (tranexamic acid), replace fibrinogen.
- 9.
A patient taking an anticoagulant presents with an intracranial haemorrhage. How does the drug class guide reversal?
Show answer
- Identify the drug and the time of the last dose; check renal function.
- Warfarin: vitamin K plus prothrombin complex concentrate for immediate effect.
- Dabigatran: idarucizumab; dialysis is an option because it is dialysable.
- Factor Xa inhibitors: andexanet alfa where available, otherwise prothrombin complex concentrate.
- Heparin: protamine, complete for unfractionated, partial for low molecular weight.
- Antiplatelets: no antidote; platelet transfusion is of uncertain benefit.
Practise this week
- First Part MCQs: haematology and transfusion
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 18 in the other subjects
- Physiology: Synapses, neuromuscular junction and muscle
- Measurement: Neuromuscular and depth of anaesthesia monitoring
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.